loading page

Shared proteomic patterns among high BMI and comorbidities may indicate potential biomarkers in a Brazillian population
  • +5
  • Carlos Vinicius da Silva,
  • Carlos José Ferreira Da Silva,
  • Sandra Mara Naressi Scapin,
  • Youssef Bacila Sade,
  • Cristiane Carneiro Thompson,
  • FABIANO THOMPSON,
  • Carina Maciel da Silva-Boghossian,
  • Eidy de Oliveira Santos
Carlos Vinicius da Silva
UFRJ
Author Profile
Carlos José Ferreira Da Silva
UERJ
Author Profile
Sandra Mara Naressi Scapin
Inmetro
Author Profile
Youssef Bacila Sade
Inmetro
Author Profile
Cristiane Carneiro Thompson
UFRJ
Author Profile
FABIANO THOMPSON
UFRJ
Author Profile
Carina Maciel da Silva-Boghossian
UFRJ
Author Profile
Eidy de Oliveira Santos
UERJ

Corresponding Author:eidyos@gmail.com

Author Profile

Abstract

This study sought to analyze the impact of Metabolic Syndrome (MeS) and Type 2 Diabetes (T2DM) on metabolism and their relationship of Body Mass Index (BMI) and to identify potential predictive protein biomarkers for MeS and T2DM. The proteomes of saliva and blood, clinical parameters were analyzed in 103 adult individuals from the State of Rio de Janeiro, Brazil, a mixed-race population. Healthy individuals were sorted by their Body Mass Index (BMI) in normal (n=29), overweight (n=25) and obese (n=15) and were compared with individuals with MeS (n=23) and T2DM (n=11). Random forest predictive model revealed that 3 clinical variables, BMI, HOMA-IR, and fasting blood glucose, are most important for predicting MeS and T2DM. A total of 6 plasmatic proteins (ABCD4, LDB1, PDZ, Podoplanin, Lipirin-alpha-3 and WRS) and 6 salivary proteins (Hemoglobin subunit beta, POTE ankyrin domain family member E, T cell receptor alpha variable 9-2, Lactotransferrin, Cystatin-S, Carbonic anhydrase 6), are enhanced in T2DM and in MeS. Salivary and plasmatic proteomes, in a population of brazil, demonstrates that the physiopathological conditions associated with abnormal weight gain, T2DM, and MeS share similar modifications in protein composition, offering potential predictive biomarkers, potentially mitigating the adverse health consequences of these metabolic disorders.
Submitted to Clinical Applications
10 Apr 2024Review(s) Completed, Editorial Evaluation Pending
10 Apr 2024Editorial Decision: Revise Major
31 May 20241st Revision Received
05 Jul 2024Reviewer(s) Assigned
17 Jul 2024Review(s) Completed, Editorial Evaluation Pending
18 Jul 2024Editorial Decision: Accept